MILAN, Oct. 6, 2026 /PRNewswire/ — Zhejiang Hisun Pharmaceutical Co., Ltd. hosted its 70th Anniversary Global Partners Appreciation Dinner in Milan on October 5, the eve of CPHI Milan 2026. Themed “Bridging Cultures, Advancing Health Together,” the event brought together leading pharmaceutical companies from around the world for an evening of networking and cultural exchange. Mr. Geng Xiewei, Economic and Commercial Counsellor of the Consulate General of the People’s Republic of China in Milan; representatives of Chinese and Italian business associations, including the China Chamber of Commerce in Italy and the Milan Overseas Chinese Chamber of Commerce; and representatives of leading global pharmaceutical companies. Through industry networking and cultural exchange, the guests renewed bonds of partnership and explored new avenues for cooperation. The event also highlighted both the strength of the pharmaceutical industry cluster in Taizhou, Zhejiang province and Hisun Pharmaceutical’s 70-year commitment to pharmaceutical manufacturing and international cooperation.
Mr. Geng Xiewei, Economic and Commercial Counsellor of the Consulate General of the People’s Republic of China in Milan delivered a speech
Mr. Juan Carlos Alvarez, Board Member of PiSA FARMACEUTICA delivered a speech
Mr. Kevin Xiao, Chairman & CEO, Hisun Pharmaceutical delivered a speech
The event took inspiration from Taizhou’s distinctive frameless lanterns and featured a lantern-lighting ceremony inspired by the city’s natural landscapes, cultural experiences showcasing its traditional arts and crafts, and displays of local specialties. These activities offered international guests a glimpse into Taizhou’s rich cultural heritage and the vitality of its pharmaceutical industry, which has earned the city recognition as the “Pharmaceutical Capital of China.” The event also helped raise the international profile of both Taizhou and Hisun Pharmaceutical.
Founded in 1956 in Taizhou, Hisun Pharmaceutical was a pioneer in bringing Chinese pharmaceuticals to international markets. In 1992, its tobramycin received U.S. FDA approval. As one of the earliest Chinese companies to export active pharmaceutical ingredients (APIs), Hisun began its commercial expansion in established markets, including the U.S. and Europe. Since then, the company has built its international business around high-quality specialty APIs. Several of its core products have obtained Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEPs), and its manufacturing facilities have received EU Good Manufacturing Practice (GMP) certification, supporting its long-standing ties with the European pharmaceutical industry.
In 2025, Hisun Pharmaceutical launched its Internationalization 2.0 Strategy, with a focus on deeper engagement in overseas markets, a stronger local presence and broader collaboration across the value chain. The company continues to strengthen strategic partnerships with leading European pharmaceutical companies and research institutions, expanding collaboration beyond API supply to encompass joint R&D, technology transfer, local manufacturing and cooperation in regulated markets. These efforts are building closer collaboration between the Chinese and European pharmaceutical industries.
Over the past 70 years, Hisun Pharmaceutical has grown into an integrated pharmaceutical and healthcare group with capabilities spanning R&D, manufacturing and sales. Its products are sold in more than 100 countries and regions worldwide, with international businesses in APIs, finished pharmaceutical products and animal health. The company continues to serve the global pharmaceutical industry through its commitment to quality and its manufacturing expertise in China.
A scene from the gala
The “Milan-Taizhou Night” provided a platform for cultural exchange and industry dialogue with the global pharmaceutical community, while also strengthening Hisun Pharmaceutical’s connections with international partners. As Hisun Pharmaceutical marks its 70th anniversary, the company will continue to deepen international collaboration and work with partners around the world to foster innovation and shared progress across the pharmaceutical industry.
